Cargando…
Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells
BACKGROUND: Drug resistance is one of the major problems encountered in clinical therapy of multiple myeloma treatment. Combination treatment with several drugs may increase the sensitivity and overcome drug resistance. METHODS: Here, we combined chemotherapy with a newly developed technology, cold...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798238/ https://www.ncbi.nlm.nih.gov/pubmed/35117041 http://dx.doi.org/10.21037/tcr.2019.10.43 |
Sumario: | BACKGROUND: Drug resistance is one of the major problems encountered in clinical therapy of multiple myeloma treatment. Combination treatment with several drugs may increase the sensitivity and overcome drug resistance. METHODS: Here, we combined chemotherapy with a newly developed technology, cold atmospheric plasma, to enhance drug sensitivity. RESULTS: We found that plasma treatment had a synergistic anti-cancer effect with a first line drug (bortezomib). Based on our previous study, we further found that plasma treatment could inhibit Notch pathway and down-regulate cyp1a1 expression and enzyme activity, which contributing to the enhanced drug sensitivity to bortezomib after combination of bortezomib with gas plasma. CONCLUSIONS: Our results showed a new strategy to overcome drug resistance by combination of traditional chemotherapy with cold atmospheric plasma. |
---|